Physician profile
Evan L Nelson
NPI 1053375212
$656.04
in general payments reported to CMS, 2019-2025
11 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $35.57 · 2023: $127 · 2024: $154 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $620.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $119.77 | 2023-2025 | |
| Harmony Biosciences LLC | $104.39 | 2023-2025 | Wakix |
| Teva Pharmaceuticals USA, INC. | $103.52 | 2022-2025 | Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $80.09 | 2023-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $57.02 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $56.78 | 2023 | Ingrezza |
| Indivior INC. | $46.81 | 2022-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $34.66 | 2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $19.22 | 2024 | |
| Alkermes, INC. | $17.89 | 2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $15.89 | 2025 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.